Congailure
-
Upload
flavio-guzman -
Category
Health & Medicine
-
view
17.327 -
download
0
Transcript of Congailure
![Page 1: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/1.jpg)
Congestive Cardiac FailureCongestive Cardiac Failure
Dr. R. Senthil Kumar
![Page 2: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/2.jpg)
Introduction to Heart FailureIntroduction to Heart Failure
• Heart unable to provide adequate perfusion of peripheral organs to meet their metabolic requirements
• Characterized by:
1. Reduction in cardiac output
2. Increased TPR• Progressing to congestive heart failure (CHF) is
accompanied by peripheral and pulmonary edema.
![Page 3: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/3.jpg)
Recent Advances Vs RealityRecent Advances Vs Reality
• Major advances in recent years in management of patients with CHF
• In 2000 an estimated 4.7 million people in the United States had HF
• The median survival after initial diagnosis is 1.7 years for men and 3.2 years for women.
• Sudden cardiac death is common in patients with heart failure, contributing to 50% of all 287,000 deaths in the United States last year
![Page 4: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/4.jpg)
Acute Vs Chronic HFAcute Vs Chronic HF
• In a patient with acute heart failure, the short-term aim is stabilization by providing symptomatic treatment through intravenous interventions.
• Management of chronic heart failure is multifaceted, with the long-term aims of:• relieving symptoms• improving hemodynamics• improving quality of life and • decrease mortality.
![Page 5: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/5.jpg)
Cardiac Vs Noncardiac targetsCardiac Vs Noncardiac targets
• Conventional belief that the primary defect in HF is in the heart
• Reality is that HF involves many other processes and organs
• Research has shown that therapy directed at noncardiac targets are more valuable than cardiac targets
![Page 6: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/6.jpg)
Compensation in HFCompensation in HF
• Heart failure is usually accompanied by an increase in:
1. Sympathetic nervous system (SNS) 2. Chronic up-regulation of the renin-
angiotensin-aldosterone system (RAAS) and effects of aldosterone on heart, vessels, and kidneys.
• CHF should be viewed as a complex, interrelated sequence of events involving hemodynamic, and neurohormonal events.
![Page 7: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/7.jpg)
Compensation contd..Compensation contd..
• In a failing heart, the loss of contractile function leads to a decline in CO and a decrease in arterial BP.
• Baroreceptors sense the hemodynamic changes and initiate countermeasures to maintain support of the circulatory system.
• Activation of the SNS serves as a compensatory mechanism in response to the earlier
• This helps maintain adequate cardiac output by:1. Increasing myocardial contractility and heart rate (β1-
adrenergic receptors)2. Increasing vasomotor tone (α1-adrenergic receptors)
to maintain systemic blood pressure
![Page 8: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/8.jpg)
Consequences of hyperadrenergic Consequences of hyperadrenergic statestate• Over the long term, this hyperadrenergic state
leads to irreversible myocyte damage, cell death, and fibrosis.
• In addition, the augmentation in peripheral vasomotor tone increases LV afterload
• This places an added stress upon the left ventricle and an increase in myocardial O2 demand (ventricular remodeling).
• The frequency and severity of cardiac arrhythmias are enhanced in the failing heart
![Page 9: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/9.jpg)
• Figure p.203 kat
![Page 10: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/10.jpg)
PathophysiologyPathophysiology
• CHF pathophysiology animation
![Page 11: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/11.jpg)
Therapeutic Overview Therapeutic Overview
Problem• Reduced force of contraction• Decreased cardiac output• Increased total peripheral resistance• Inadequate organ perfusion• Development of edema• Decreased exercise tolerance• Ischemic heart disease• Sudden death• Ventricular remodeling and decreased function
![Page 12: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/12.jpg)
Goals and drug therapyGoals and drug therapy
Goals• Alleviation of symptoms, improve quality of life• Arrest ventricular remodeling• Prevent sudden death Nondrug therapy• Reduce cardiac work; rest, weight loss, low Na+ diet Drug therapy• Chronic heart failure
• ACE-I, β-blockers, ARB, aldosterone antagonists, digoxin, diuretics • Acute heart failure
• Intravenous diuretics, inotropic agents, PDE inhibitors, vasodilator
![Page 13: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/13.jpg)
Signs and symptomsSigns and symptoms
• Tachycardia• Decreased exercise tolerance & SOB• Peripheral and pulmonary edema• Cardiomegaly
![Page 14: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/14.jpg)
![Page 15: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/15.jpg)
DiureticsDiuretics
• Bottom line: they decrease fluid volumes
• Four Flavours:• Carbonic anhydrase inhibitors• Loop diuretics• Thiazide diuretics• K+-sparing
![Page 16: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/16.jpg)
Renin angiotensin systemRenin angiotensin system• Baroreceptor mediated activation of the SNS
leads to an increase in renin release and formation of angiotensin II
• Angiotensin II acts through AT1 and AT2 receptors (most of its actions occur through AT1 receptors)
• This causes vasoconstriction and stimulates aldosterone production
• RAS remains the most important target of chronic CHF therapy
![Page 17: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/17.jpg)
Effects of AT-IIEffects of AT-II
![Page 18: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/18.jpg)
MOAMOA• ACE-Inhibitors and ARB animation• Blockade of ACE• Decreased AT-II• Decreased aldosterone• Decreased fluid retention• Vasodilation• Reduced preload and afterload• Slows cardiac remodeling
![Page 19: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/19.jpg)
Advantages Advantages
• Improves symptoms significantly• Improves exercise tolerance• Slows progression of the disease• Prolong survival in established cases
![Page 20: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/20.jpg)
ADRADR
• What are the ADR of ACEIs?• Cough (why?)• Postural hypotention (why?)• Hyperkalemia (possible Drug interactions?)• Contraindicated in pregnant women (1st
trimester)• Rare: angioedema
![Page 21: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/21.jpg)
Other Vasodilators:Other Vasodilators:
• Mechanism 2: • Direct smooth muscle relaxants• Nitrates
• Venous dilators• Reduce preload• Eg: sodium nitropruside
![Page 22: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/22.jpg)
InotropesInotropes
• Increase force of contraction• All increase intracellular cardiac Ca++
concentration• Eg:
• Digitalis (cardiac glycoside)• Dobutamine (β-adrenergic agonist)• Amrinone (PDE inhibitor)
![Page 23: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/23.jpg)
Cardiac glycosidesCardiac glycosides
• Digitalis • Sourced from foxglove plant• 1785, Dr. William Withering’s
monograph on digitalis• Has a profound effect on the cardiac
contractility
![Page 24: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/24.jpg)
![Page 25: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/25.jpg)
PckPck
• Two drugs (digoxin, digitoxin)• Well absorbed orally• 10% of population have bacteria in the gut,
which inactivate digoxin, needing an increased dose in such
• Beware of using antibiotics in such patients• Digoxin has a very narrow ther. Margin
![Page 26: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/26.jpg)
PckPck
• Taken orally• Enters CNS (so what?)• Renal clearance proportional to CC• To be used with extreme caution in
patients suffering from renal impairment
![Page 27: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/27.jpg)
MOAMOA
• Regulation of cytosolic Ca metabolism:• Reversibly combine with sodium-potassium
ATPase of the cardiac cell membrane• Results in inhibition of pump activity• This leads to in intracellular Na conc.• This favors Ca ions in the cell• Ca levels result in increased systolic force of
contraction
![Page 28: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/28.jpg)
Digoxin MOADigoxin MOA
![Page 29: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/29.jpg)
Na/K ATPase inhibitionNa/K ATPase inhibition
![Page 30: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/30.jpg)
Additional MOAAdditional MOA
• Force of contraction resembles to that of the normal heart
• Improved circulation leads to reduced sympathetic activity
• This reduces PVR• All this leads to reduction in HR• Vagal tone is enhanced• Finally myocardial O2 demand is reduced
![Page 31: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/31.jpg)
Electrophysiological effects on the Electrophysiological effects on the heart heart
![Page 32: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/32.jpg)
Uses Uses
• Severe LV systolic dysfunction• Only after initiation of diuretics and
vasodialtor therapy• Management of patients with chronic atrial
fibrillation• Cannot arrest the progression of pathological
changes causing heart failure, and does not prolong life in patients with CHF
![Page 33: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/33.jpg)
ADRADR
• Digitalis toxicity is one among most commonest encountered (why?)
• Therapeutic concentration- 0.5-1.5 ng/ml• Often the first step is discontinuation of Rx• Digoxin levels must be monitored closely
![Page 34: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/34.jpg)
Signs of digoxin toxicitySigns of digoxin toxicity
• CNS: Malaise, confusion, depression, vertigo, vision (abnormalities in color vision)
• GI: Anorexia, nausea, intestinal cramping, diarrhea
• Cardiovascular: Palpitations, syncope, arrhythmias, bradycardia, AV node block, tachycardia
![Page 35: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/35.jpg)
Factors increasing the possibility of Factors increasing the possibility of digoxin toxicitydigoxin toxicity• Pharmacological and toxic effects are greater
in hypokalemic patients.• K+-depleting diuretics are a major
contributing factor to digoxin toxicity.
![Page 36: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/36.jpg)
Management Management Arrhythmias may be converted to normal
sinus rhythm by K+. when the plasma K+ conc. is low or within the normal range.
When the plasma K+ conc. is high, antiarrhythmic drugs, such as lidocaine, procainamide, or propranolol, can be used.
Severe toxicity treated with Digibind, an anti-digoxin antibody.
![Page 37: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/37.jpg)
• A 96-year-old AAF was admitted from a nursing home with complaints of abdominal pain, N/V, dizziness, confusion and double vision for 5 days. She was discharged from the hospital just 4 days ago. Digoxin was started during that previous hospitalization for control of tachycardia in atrial fibrillation. One day prior to discharge, digoxin level was 1.8 mg/mL and digoxin dose was decreased to 125 mcg PO Q 48 hr.PMHHypertension, atrial fibrillation, coronary artery disease, stroke, congestive heart failure.MedicationsMetoprolol, Digoxin, ASA, lisinopril, Lasix, Coumadin, Nexium
What could it be???What could it be???
![Page 38: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/38.jpg)
DopamineDopamine• Dopamine acts at a variety of
receptors (dose dependant)• Rapid elimination- can only be
administered as a continuous infusion
![Page 39: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/39.jpg)
DobutamineDobutamine• Stimulates beta-adrenergic receptors and
produces a positive inotropic response • Unlike the vasoconstriction seen with high
doses of dopamine, dobutamine produces a mild vasodilatation
![Page 40: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/40.jpg)
MOAMOA
![Page 41: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/41.jpg)
PDE inhibitors PDE inhibitors • Inamrinone (amrinone) and Milrinone
(bipyridines)• Acts by inhibiting the enzyme Phosphodiesterase• Thus lead to increase of intracellular
concentrations of cAMP• cAMP is responsible for the conversion of
inactive protein kinase to active form• Protein kinases are responsible for
phosphorylation of Ca channels • Thus causing increased Ca entry into the cell.
![Page 42: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/42.jpg)
MOAMOA
• Increase myocardial contractility by increasing the Ca influx during AP
• Also have vasodilating effect• Selective for PDE isoenzyme-3 (found
in cardiac and smooth muscle)
![Page 43: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/43.jpg)
Current statusCurrent status
• Both are orally active• Only available in parenteral forms• Limited efficacy• Clinical trials- increased mortality (oral)• Still new drugs are under trial
![Page 44: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/44.jpg)
ADRADR
• Inamrinone: nausea, vomiting, arrhythmias, thrombocytopenia and liver enzyme changes
• Withdrawn in some countries• Milrinone: arrhythmias, less likely to
cause other ADR
![Page 45: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/45.jpg)
(BNP)-Niseritide(BNP)-Niseritide
• Brain (B-type) natriuretic peptide (BNP) is secreted constitutively by ventricular myocytes in response to stretch
• BNP binds to receptors in the vasculature, kidney, and other organs, producing potent vasodilation with rapid onset and offset of action by increasing levels of cGMP
• Niseritide is recombinant human BNP approved for treatment of acute decompensated CHF.
![Page 46: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/46.jpg)
BNP contd..BNP contd..
• It reduces systemic and pulmonary vascular resistances, causing an indirect increase in cardiac output and diuresis.
• Effective in HF because cause reduction in preload and afterload
• ADR- hypotension
![Page 47: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/47.jpg)
Beta blockersBeta blockers
• Overwhelming evidence to support the use of β-blockers in CHF, however
• Mechanism involved remain unclear • Part of their beneficial effects may derive
from slowing of heart rate and decrease myocardial O2consumption.
• This would lessen the frequency of ischemic events and potential for development of a lethal arrhythmia.
![Page 48: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/48.jpg)
Beta blockersBeta blockers
• Suggested mechanisms also include reduced remodeling
• β-Blockers may be beneficial through resensitization of the down-regulated receptor, improving myocardial contractility.
• Recent studies with bisoprolol, carvedilol and metoprolol showed a reduction in mortality in patients with these drugs
• CI in unstable cases
![Page 49: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/49.jpg)
Management of Chronic HFManagement of Chronic HF(combination of drugs) (combination of drugs)
• Limit physical activity• Reduce weight• Reduce water intake• Control HT• Na restriction• Diuretics• ACE-Is• Digitalis (ther. margin, DI with quinidine) • Beta blockers• Vasodilators
![Page 50: Congailure](https://reader035.fdocuments.net/reader035/viewer/2022062703/55505f1cb4c905ae3f8b52ab/html5/thumbnails/50.jpg)
Management of acute HFManagement of acute HF
• Diuretics• Vasodilators• Inotropic drugs• Life support• Treating cause (surgery to correct
valvular disorders)